Page 20 of 44.
A comprehensive clinical and harm-reduction guide to Midazolam in India, exploring its role in procedural sedation, the life-saving potential of nasal sprays in pediatric seizures, Jan Aushadhi pricing, and safety protocols as of 2026.
A comprehensive clinical and harm-reduction guide to Chlordiazepoxide (Librium) in India, exploring its history as the first benzo, its vital role in alcohol detox, Jan Aushadhi pricing, and its combination use for IBS as of 2026.
A comprehensive clinical and harm-reduction guide to Clobazam in India, exploring its unique 1,5-benzodiazepine structure, its role in treating difficult epilepsies, Jan Aushadhi pricing, and the intermittent dosing protocols for catamenial epilepsy as of 2026.
A comprehensive clinical and harm-reduction guide to Zolpidem (Zolfresh) in India, exploring its selective GABA-A action, the risk of complex sleep behaviors, Jan Aushadhi pricing, and its paradoxical effect on brain injuries as of 2026.
A comprehensive clinical and harm-reduction guide to Zopiclone in India, exploring its cyclopyrrolone pharmacology, the hallmark 'metallic taste,' Jan Aushadhi unavailability, and its April 2026 shift to Schedule H1.
A comprehensive clinical and harm-reduction guide to Eszopiclone in India, exploring its (S)-enantiomer advantage, its role in chronic insomnia management, market pricing, and the strict 2026 Schedule H1 regulations.
A comprehensive clinical and harm-reduction guide to Phenobarbital in India, exploring its role as an essential antiepileptic, Jan Aushadhi pricing, the dangers of barbiturate withdrawal, and its extreme 100-hour half-life as of 2026.
A comprehensive clinical and harm-reduction guide to Tramadol Hydrochloride in the Indian context, covering pharmacology, NDPS regulations, and market pricing as of 2026.
A comprehensive clinical and harm-reduction guide to Pentobarbital in India, exploring its role in 'Barbiturate Comas,' its veterinary use for humane euthanasia, Jan Aushadhi unavailability, and the strict Schedule X legal status as of 2026.
A comprehensive clinical and harm-reduction guide to Pregabalin in India, exploring its role in nerve pain and anxiety, its Jan Aushadhi pricing, the rising trend of its misuse as 'The New Tramadol,' and the April 2026 Schedule H1 update.
A comprehensive clinical and harm-reduction guide to Gabapentin (Neurontin) in India, exploring its saturable absorption kinetics, Jan Aushadhi pricing, its role in treating Shingles pain, and the April 2026 shift to Schedule H1.
A comprehensive clinical and harm-reduction guide to Carisoprodol in India, exploring its conversion to Meprobamate, Jan Aushadhi unavailability, its rising misuse in the 'Pharma-Free' export market, and the April 2026 shift to Schedule H1.